Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Exact Sciences

Why IBD 50's Guardant Health Just Tumbled, Breaking A 67% Monthlong Run

Guardant Health stock took a tumble Thursday after the company's second-generation colon cancer test lagged expectations in a pivotal study.

Investors Business Daily

Top 3 Health Care Stocks That Are Preparing To Pump This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga

Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst

Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal?

Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer test.

Investors Business Daily

IBD Rating Upgrades: Exact Sciences Flashes Improved Price Strength

Exact Sciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Exact Sciences Clears Technical Benchmark, Hitting 80-Plus RS Rating

Exact Sciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 84.

Investors Business Daily

Exact Sciences Hits 80-Plus Relative Strength Rating Benchmark

Exact Sciences sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Exact Sciences Earns IBD Rating Upgrade

Exact Sciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Exact Sciences Hikes Its Full-Year Outlook. But There's One First-Quarter Drawback.

Exact Sciences hiked two elements of its outlook late Thursday, despite coming in with a mixed earnings report.

Investors Business Daily

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.

A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Investors Business Daily

How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain

Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.

Investors Business Daily

Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone

Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test.

Investors Business Daily

Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?'

Exact Sciences stock crumbled Thursday on its growing rivalry with Guardant Health and Natera in colon cancer screening.

Investors Business Daily

What 19 Analyst Ratings Have To Say About Exact Sciences

19 analysts have shared their evaluations of Exact Sciences (NASDAQ:EXAS) during the recent three months, expressing a mix of bullish and bearish perspectives.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop

Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.

Investors Business Daily

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook.

Investors Business Daily

Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook

Exact Sciences stock fell sharply Tuesday after the company cut its full-year outlook and posted weaker-than-expected results.

Barchart

1 'Strong Buy' Healthcare Stock to Scoop Up After Its Latest FDA Win

This top-rated healthcare stock is poised for substantial growth after securing FDA approval for its innovative non-invasive cancer diagnostic.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Exact Sciences Stock Rises After FDA Signs Off On New Cologuard

Exact Sciences stock rose Friday after the FDA approved the company's next-generation colon cancer detection test, Cologuard Plus.

Investors Business Daily

Why Exact Sciences, Up 27%, Is 'Coiled To Snap Back' After Quarterly Beat

Exact Sciences stock bounded higher Thursday after beating second-quarter expectations, signaling a return to growth for Cologuard.

Investors Business Daily

Guardant Health Jumps — As Exact Sciences Slumps — On A Key FDA Move For Blood Tests

Guardant Health stock jumped Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.

Investors Business Daily

Exact Sciences Stock, A Cathie Wood Darling, Tumbles On 'Overblown' Growth Concerns

Exact Sciences stock tumbled early Thursday as fears of a sales slowdown spooked investors in the Cologuard maker.

Investors Business Daily

Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales

Exact Sciences stock surged Tuesday after the company's colon cancer-screening rival, Freenome, unveiled the results of a pivotal study.

Investors Business Daily

Cathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer Updates

Exact Sciences stock fell early Thursday after the company said its next-generation Cologuard beat a rival stool-based screening test.